Oriental Science and Technology Forum: Relationship between Microenvironment and Stem Cells and Bone

The 195th Oriental Science and Technology Forum was held in Shanghai recently. Experts at home and abroad have discussed the effects of microenvironment and systemic factors on the growth of bone tumors, the research of cancer stem cells and osteosarcoma, the new technology of cancer treatment, and the strategy of cancer surgical treatment.

Malignant tumors are one of the main causes of human death, second only to heart disease. Primary bone malignant tumors account for about 1% of adult malignant tumors and 10% of children's malignant tumors.

Dai Rong, academician of the Chinese Academy of Engineering, said that as a common complication of advanced malignant tumors, the incidence of metastatic bone tumors has increased significantly in recent years. According to statistics, the incidence of metastatic bone tumors accounts for about 15%-20% of all metastatic tumors in the whole body, second only to lung and liver metastases, ranking third; about 70% of breast cancer, prostate cancer and other osteophilic tumors occur bone metastases in the natural course of disease, and 15%-30% of lung cancer, gastric cancer, colorectal cancer, renal cancer, thyroid cancer and other patients also have bone metastases.

Clinically, primary and metastatic bone tumors often lead to severe local pain, pathological fractures, life-threatening hypercalcemia and spinal cord compression, which seriously affect the quality of life of patients. Experts at the meeting believed that bone tumors are more closely related to the microenvironment and stem cells than other tumors because of their special cellular origin (most of them originate from mesenchymal and/or osteoblast) and location of onset (most of them occur in bone marrow cavity and adjacent bone tissue).

Dai Rong said that the research on the relationship between microenvironment and stem cells and bone tumors is one of the frontiers of cancer research. It will greatly promote the progress of research on the pathogenesis, surface markers, molecular targets and drug development of bone tumors and other tumors, so as to provide new reference for clinical treatment of bone tumors.
Related News